Elevated Pretherapy Serum IL17 in Primary Hepatocellular Carcinoma Patients Correlate to Increased Risk of Early Recurrence after Curative Hepatectomy

PLoS ONE

Volumn 7, Issue 12, 2012, Pages

  Wu, Jianxiong ^a   Du, Jun ^a   Liu, Liguo ^a   Li, Qian ^a,b   Rong, Weiqi ^a   Wang, Liming ^a   Wang, Ying ^a   Zang, Mengya ^a   Wu, Zhiyuan ^a   Zhang, Yawei ^b   Qu, Chunfeng ^a  

^a PEKING UNION MEDICAL COLLEGE   (China)

^b YALE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 10; INTERLEUKIN 17; INTERLEUKIN 17 ANTIBODY; INTERLEUKIN 17A ANTIBODY; NEUTRALIZING ANTIBODY; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CANCER PATIENT; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SURVIVAL; CELL PROLIFERATION; COCULTURE; COHORT ANALYSIS; CONTROLLED STUDY; CYTOKINE PRODUCTION; FEMALE; HEPATITIS B; HIGH RISK PATIENT; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; INTERLEUKIN 10 BLOOD LEVEL; INTERLEUKIN 17 BLOOD LEVEL; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER RESECTION; LYMPHOCYTIC INFILTRATION; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIMARY TUMOR; PROTEIN BLOOD LEVEL; RECURRENCE RISK; REGULATORY T LYMPHOCYTE; RISK FACTOR; TH1 CELL; TH17 CELL; TH2 CELL; TUMOR VOLUME;

CARCINOMA, HEPATOCELLULAR; CELL SEPARATION; COHORT STUDIES; FEMALE; FLOW CYTOMETRY; HEPATECTOMY; HUMANS; INTERLEUKIN-17; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PREOPERATIVE PERIOD; PROGNOSIS; RISK FACTORS;

HEPATITIS B VIRUS;

EID: 84870847993     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0050035     Document Type: Article

References (34)

1. Marin-Hargreaves G, Azoulay D, Bismuth H, (2003) Hepatocellular carcinoma: surgical indications and results. Crit Rev Oncol Hematol 47: 13-27.
2. Llovet JM, (2005) Updated treatment approach to hepatocellular carcinoma. J Gastroenterol 40: 225-235.
3. Poon D, Anderson BO, Chen LT, Tanaka K, Lau WY, et al. (2009) Management of hepatocellular carcinoma in Asia: consensus statement from the Asian Oncology Summit 2009. Lancet Oncol 10: 1111-1118.
4. Omata M, Lesmana LA, Tateishi R, Chen PJ, Lin SM, et al. (2010) Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma. Hepatol Int 4: 439-474.
5. Imamura H, Matsuyama Y, Tanaka E, Ohkubo T, Hasegawa K, et al. (2003) Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy. J Hepatol 38: 200-207.
6. Ye QH, Qin LX, Forgues M, He P, Kim JW, et al. (2003) Predicting hepatitis B virus-positive metastatic hepatocellular carcinomas using gene expression profiling and supervised machine learning. Nat Med 9: 416-423.
7. Lee JS, Thorgeirsson SS, (2004) Genome-scale profiling of gene expression in hepatocellular carcinoma: classification, survival prediction, and identification of therapeutic targets. Gastroenterology 127: S51-55.
8. Budhu A, Forgues M, Ye QH, Jia HL, He P, et al. (2006) Prediction of venous metastases, recurrence, and prognosis in hepatocellular carcinoma based on a unique immune response signature of the liver microenvironment. Cancer Cell 10: 99-111.
9. Hoshida Y, Villanueva A, Kobayashi M, Peix J, Chiang DY, et al. (2008) Gene expression in fixed tissues and outcome in hepatocellular carcinoma. N Engl J Med 359: 1995-2004.
10. Ming L, Thorgeirsson SS, Gail MH, Lu P, Harris CC, et al. (2002) Dominant role of hepatitis B virus and cofactor role of aflatoxin in hepatocarcinogenesis in Qidong, China. Hepatology 36: 1214-1220.
11. Chisari FV, Isogawa M, Wieland SF, (2010) Pathogenesis of hepatitis B virus infection. Pathol Biol (Paris) 58: 258-266.
12. Guidotti LG, Chisari FV, (2006) Immunobiology and pathogenesis of viral hepatitis. Annu Rev Pathol 1: 23-61.
13. Zhu J, Yamane H, Paul WE, (2010) Differentiation of effector CD4 T cell populations (*). Annu Rev Immunol 28: 445-489.
14. Seike M, Yanaihara N, Bowman ED, Zanetti KA, Budhu A, et al. (2007) Use of a cytokine gene expression signature in lung adenocarcinoma and the surrounding tissue as a prognostic classifier. J Natl Cancer Inst 99: 1257-1269.
15. Enewold L, Mechanic LE, Bowman ED, Zheng YL, Yu Z, et al. (2009) Serum concentrations of cytokines and lung cancer survival in African Americans and Caucasians. Cancer Epidemiol Biomarkers Prev 18: 215-222.
16. Chew V, Tow C, Teo M, Wong HL, Chan J, et al. (2010) Inflammatory tumour microenvironment is associated with superior survival in hepatocellular carcinoma patients. J Hepatol 52: 370-379.
17. Pandey D, Lee KH, Wai CT, Wagholikar G, Tan KC, (2007) Long term outcome and prognostic factors for large hepatocellular carcinoma (10 cm or more) after surgical resection. Ann Surg Oncol 14: 2817-2823.
18. Dahiya D, Wu TJ, Lee CF, Chan KM, Lee WC, et al. (2010) Minor versus major hepatic resection for small hepatocellular carcinoma (HCC) in cirrhotic patients: a 20-year experience. Surgery 147: 676-685.
19. Wu M, Shen F (2010) Liver Cancer. 2010.3 ed. Beijing: Peking University Medical Press. 327.
20. Qu C, Moran TM, Randolph GJ, (2003) Autocrine type I IFN and contact with endothelium promote the presentation of influenza A virus by monocyte-derived APC. J Immunol 170: 1010-1018.
21. Kuang DM, Peng C, Zhao Q, Wu Y, Chen MS, et al. (2010) Activated monocytes in peritumoral stroma of hepatocellular carcinoma promote expansion of memory T helper 17 cells. Hepatology 51: 154-164.
22. Kryczek I, Banerjee M, Cheng P, Vatan L, Szeliga W, et al. (2009) Phenotype, distribution, generation, and functional and clinical relevance of Th17 cells in the human tumor environments. Blood 114: 1141-1149.
23. Huang R, Xing Z, Luan Z, Wu T, Wu X, et al. (2003) A specific splicing variant of SVH, a novel human armadillo repeat protein, is up-regulated in hepatocellular carcinomas. Cancer Res 63: 3775-3782.
24. Yan J, Yu Y, Wang N, Chang Y, Ying H, et al. (2004) LFIRE-1/HFREP-1, a liver-specific gene, is frequently downregulated and has growth suppressor activity in hepatocellular carcinoma. Oncogene 23: 1939-1949.
25. Wilson NJ, Boniface K, Chan JR, McKenzie BS, Blumenschein WM, et al. (2007) Development, cytokine profile and function of human interleukin 17-producing helper T cells. Nat Immunol 8: 950-957.
26. Boniface K, Blom B, Liu YJ, de Waal Malefyt R, (2008) From interleukin-23 to T-helper 17 cells: human T-helper cell differentiation revisited. Immunol Rev 226: 132-146.
27. Zhang JY, Zhang Z, Lin F, Zou ZS, Xu RN, et al. (2010) Interleukin-17-producing CD4(+) T cells increase with severity of liver damage in patients with chronic hepatitis B. Hepatology. 51: 81-91.
28. Wang L, Yi T, Zhang W, Pardoll DM, Yu H, (2010) IL-17 enhances tumor development in carcinogen-induced skin cancer. Cancer Res 70: 10112-10120.
29. He D, Li H, Yusuf N, Elmets CA, Athar M, et al. (2012) IL-17 Mediated Inflammation Promotes Tumor Growth and Progression in the Skin. PLoS One 7: e32126.
30. He D, Li H, Yusuf N, Elmets CA, Li J, et al. (2010) IL-17 promotes tumor development through the induction of tumor promoting microenvironments at tumor sites and myeloid-derived suppressor cells. J Immunol 184: 2281-2288.
31. Zhang JP, Yan J, Xu J, Pang XH, Chen MS, et al. (2009) Increased intratumoral IL-17-producing cells correlate with poor survival in hepatocellular carcinoma patients. J Hepatol 50: 980-989.
32. Li J, Lau GK, Chen L, Dong SS, Lan HY, et al. (2011) Interleukin 17A promotes hepatocellular carcinoma metastasis via NF-kB induced matrix metalloproteinases 2 and 9 expression. PLoS One 6: e21816.
33. Kirshberg S, Izhar U, Amir G, Demma J, Vernea F, et al. (2011) Involvement of CCR6/CCL20/IL-17 axis in NSCLC disease progression. PLoS One 6: e24856.
34. Charles KA, Kulbe H, Soper R, Escorcio-Correia M, Lawrence T, et al. (2009) The tumor-promoting actions of TNF-alpha involve TNFR1 and IL-17 in ovarian cancer in mice and humans. J Clin Invest 119: 3011-3023.